Back to Journals » Breast Cancer: Targets and Therapy » Volume 6

Multidrug-resistant breast cancer: current perspectives

Authors Martin H, Smith L, Tomlinson D

Received 15 October 2013

Accepted for publication 13 November 2013

Published 10 January 2014 Volume 2014:6 Pages 1—13

DOI https://doi.org/10.2147/BCTT.S37638

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Heather L Martin,1 Laura Smith,2 Darren C Tomlinson1

1BioScreening Technology Group, Leeds Institutes of Molecular Medicine, University of Leeds, Leeds, UK; 2Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK

Abstract: Breast cancer is the most common cancer in women worldwide, and resistance to the current therapeutics, often concurrently, is an increasing clinical challenge. By understanding the molecular mechanisms behind multidrug-resistant breast cancer, new treatments may be developed. Here we review the recent advances in this understanding, emphasizing the common mechanisms underlying resistance to both targeted therapies, notably tamoxifen and trastuzumab, and traditional chemotherapies. We focus primarily on three molecular mechanisms, the phosphatidylinositide 3-kinase/Akt pathway, the role of microRNAs in gene silencing, and epigenetic alterations affecting gene expression, and discuss how these mechanisms can interact in multidrug resistance. The development of therapeutics targeting these mechanisms is also addressed.

Keywords: PI3K/Akt, epigenetics, miRNA, ER, HER2, triple negative

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]